Antiplatelet Therapy in ACS: Choices and Controversies
Acute coronary syndrome (ACS) represents a leading cause of mortality and morbidity worldwide. Antiplatelet therapy is a cornerstone of ACS management. Explore:
- The current available antiplatelet therapies for patients with ACS
- The challenges in antiplatelet therapy selection
- The ESC and the ACC/AHA guidelines for treating both NSTE-ACS and STEMI
How do you select antiplatelet treatments for your patients with ACS? Explore the current available oral and intravenous antiplatelet drugs for ACS with insights on the latest clinical trials informing clinical guideline recommendations. Antiplatelet therapies for ACS include clopidogrel, ticagrelor and prasugrel, and dual antiplatelet therapy (DAPT) involving combination with aspirin. Also find out about the recent guidance on the management of ACS with antiplatelet therapy according to the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) in collaboration with the American Heart Association (AHA).
Antiplatelet therapy in ACS
Explore the available antiplatelet therapies for ACS patients, the challenges in treatment selection and the ESC and ACC/AHA guideline recommendations.
ACS Patient Focus
Watch our short and informative videos featuring experts Professor Robert Storey and Dr Marc P Bonaca.
Expert Opinion
Join experts Professor Robert Storey and Dr Marc P Bonaca as they discuss management strategies for patients on antiplatelet therapy.
ESC 2022 Highlights
Get an overview of all the latest developments in acute coronary syndrome (ACS) treatments, focusing on antiplatelet therapies from ESC 2022.
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.